PTO/SB/21 (0

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/511,465 **TRANSMITTAL** Filing Date February 7, 2005 **FORM** First Named Inventor Matthew H.T. Bui to be used for all correspondence after initial filing) Group Art Unit Unassigned Examiner Name Unassigned Total Number of Pages in This Submission Attorney Docket Number 306J-000220US **ENCLOSURES** (check all that apply) After Allowance Communication Χ PTO-1449 Form Fee Transmittal Form to Group Appeal Communication to Board Fee Attached Χ Copies of cited references of Appeals and Interferences Appeal Communication to Group Copy of PCT Search Report Amendment / Response X (Appeal Notice, Brief, Reply Brief) Petition Routing Slip (PTO/SB/69) After Final Proprietary Information and Accompanying Petition Affidavits/declaration(s) Petition to Convert to a Status Letter Provisional Application Power of Attorney, Revocation Additional Enclosure(s) Extension of Time Request Change of Correspondence (please identify below): Address receipt acknowledgment Terminal Disclaimer **Express Abandonment Request** postcard Small Entity Statement Information Disclosure Statement Request for Refund Certified Copy of Priority Authorization to Charge Deposit Account Document(s) Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time Response to Missing Parts/ for consideration of the documents enclosed. Incomplete Application Remarks Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Christopher C. Sappenfield, Reg. No. 45,073, Quine Intellectual Property Law Group P.C. Individual name Signature March 28, 2005 Date

CERTIFICATE OF WAILING					
hereby certify that this correspondence is being facsimile transmitted to the USPTO via fax no. 703-306-5995 or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Typed or printed name	Deborah Berwick				
Signature	Delvoh Bernel	Date Maych 29, 2005			



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450, on <u>March 39, 3005</u>

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

Deborah Berwick

Attorney Docket No. 306J-000220US Client Ref. No. 2002-463-3

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Matthew H.T. Bui, et al.

Application No.: 10/511,465

Filed: February 7, 2005

For: METHODS OF RENAL CELL

CARCINOMA PROGNOSIS AND TREATMENT SELECTION WITH CARBONIC ANHYDRASE IX Confirmation No.

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also, enclosed is a copy of International Search Report for corresponding International Application No. PCT/US2003/11561. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Matthew H.T. Bui, et al. Application No.: 10/511,465

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Christopher C. Sappenfield

Reg. No. 45,073

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458 Alameda, CA 94501 (510) 337-7871 Fax (510) 337-7877

CCS:db

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Older the Paperwork Reduction Act of 1995, no persons at	e required to respond to a conection of	Intomitation diffess it contains a valid Givib control number.	
Substitute for form 1449A-B/PTO	Complete if Known		
	Application Number	10/511,465	
INFORMATION DISCLOSURE  OF TATEMENT BY APPLICANT	Filing Date	October 14, 2004	
CSTATEMENT BY APPLICANT	First Named Inventor	Matthew H.T. Bui	
的。	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
suse as many sheets as necessary)	Attorney Docket Number	306J-000220US	
	Date Submitted	March 29, 2005	

ENT			U.	S. PATENT DOCUMENTS		
Examiner Initials	Cite No.	U.S. Patent Docu Number	Ment Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	1	2002-0137910	A1	Zavada et al.	09-26-2002	
	2	2003-0049828	A1	Zavada et al.	03-13-2003	
	3	2004-0259126	A1	Zavada et al.	12-23-2004	
	4	2005-0003425	A1	Zavada et al.	01-06-2005	
	5	2005-0031623	A1	Pastorek et al.	02-10-2005	
	6	3,766,162		Hoffmann-La Roche, Inc	10-16-1973	
	7	3,791,932		Schuurs et al.	02-12-1974	
	8	3,817,837		Rubenstein et al.	06-18-1974	
	9	4,233,402		Maggio et al.	11-11-1980	
	10	5,387,676		Zavada et al.	02-07-1995	
	11	5,955,075		Zavada et al.	09-21-1999	
	12	5,972,353		Zavada et al.	10-26-1999	
	13	5,981,711		Zavada et al.	11-09-1999	
	14	5,989,838		Zavada et al.	11-23-1999	
	15	6,004,535		Zavada et al.	12-21-1999	
	16	6,027,887		Zavada et al.	02-22-2000	
	17	6,051,226		Zavada et al.	04-18-2000	
	18	6,069,242		Zavada et al.	05-30-2000	
	19	6,093,548		Zavada et al.	07-25-2000	
	20	6,204,370	B1	Zavada et al.	03-20-2001	
	21	6,297,041	B1	Zavada et al.	10-02-2001	
	22	6,297,051	B1	Zavada et al.	10-02-2001	
	23	6,770,438	B2	Zavada et al.	08-03-2004	
	24	6,774,117	B1	Zavada et al.	08-10-2004	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons	s are required to respond to a collection of	Information unless it contains a valid Olvib control number.	
Substitute for form 1449A-B/PTO	Complete if Known		
	Application Number	10/511,465	
INFORMATION DISCLOSURE	Filing Date	October 14, 2004	
NEORMATION DISCLOSURE F STATEMENT BY APPLICANT	First Named Inventor	Matthew H.T. Bui	
<u> </u>	Group Art Unit	Unassigned	
(use as many sheets as necessary)	Examiner Name	Unassigned	
MAR 3 (use as many sheets as necessary)	Attorney Docket Number	306J-000220US	
(em. 2)	Date Submitted	March 29, 2005	
The country			

CATE IRAC	Chi.P.			FOREIGI	N PATENT DOCUMEN	TS		
Examiner Initials	Cite No.	Office	Foreign Patent Docu Number	Ment Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1
	25	wo	93/18152	A1	CIBA Corning Diagnostics Corp.	09-16-1993		
		-						

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
	26	BRETHEAU ET AL. (1995) "Prognostic value of nuclear grade of renal cell carcinoma." Cancer (Phila.) 76(12): 2543-2549.	
	27	BREWER ET AL. (1996) "A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN," <i>Gynecologic Oncology</i> 63: 337–344. (Article No. 0333)	
	28	BUI ET AL. (2001) "Prognostic factors and molecular markers for renal cell carcinoma." Expert Review of Anticancer Therapy, 1(4): 565-575.	
	29	BUI ET AL. (2003) "Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy." <i>Clinical Cancer Research</i> , 9:802-811.	
	30	DALBADIE-MCFARLAND ET AL. (1982) "Oligonucleotide-Directed Mutagenesis as a General and Powerful Method for Studies of Protein Function" <i>Proceeding of the National Academy of Sciences USA</i> , 79: 6409-6413.	
	31	DER AND STANBRIDGE (1981) "A tumor-specific membrane phosphoprotein marker in human cell hybrids." <i>Cell</i> 26: 429-438.	
. <b></b>	32	DIVGI ET AL. (1998) "Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma," <i>Clinical Cancer Research</i> , 4: 2729–2739.	-
	33	ELSON ET AL. (1988) "Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma." <i>Cancer Research</i> , 48: 7310-7313.	
	34	FIGLIN (1999) "Renal cell carcinoma: management of advanced disease." The Journal of Urology, 161:381-386.	
	35	FLANIGAN ET AL. (2001) "Nephrectomy followed by interferon $\alpha$ -2b compared with interferon $\alpha$ -2b alone for metastatic renal-cell cancer." New England Journal of Medicine, 345(23): 1655–1659.	
	36	FUHRMAN ET AL. (1982) "Prognostic significance of morphologic parameters in renal cell carcinoma." The American Journal of Surgical Pathology, 6(7): 655–663.	

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB contains as the contains a valid OMB contains as the contains

		information unless it contains a valid OMB control number.		
Substitute for form 1449A-B/PTO	C	Complete if Known		
	Application Number	10/511,465		
INFORMATION DISCLOSURE	Filing Date	October 14, 2004		
F STATEMENT BY APPLICANT	First Named Inventor	Matthew H.T. Bui		
'S\	Group Art Unit	Unassigned		
(uses many sheets as necessary)	Examiner Name	Unassigned		
R 3 (use as many sheets as necessary)	Attorney Docket Number	306J-000220US		
	Date Submitted	March 29, 2005		
· AMP				

To HADEN	
37	GALFRE AND MILSTEIN (1981) "Preparation of Monoclonal Antibodies: Strategies and Procedures." <i>Methods in Enzymology</i> , 73: 1-46.
38	GIATROMANOLAKI ET AL. (2001) "Expression of hypoxiainducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer." Cancer Research, 61:7992–7998.
39	GLENNIE AND STEVENSON (1982) "Univalent antibodies kill tumour cells in vitro and in vivo." Nature 295: 712-714.
40	GORMAN ET AL. (1991) "Reshaping a Therapeutic CD4 Antibody." Proceeding of the National Academy of Sciences USA, 88:4181-4185.
41	IVANOV ET AL. (1998) "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes," <i>Proceeding of the National Academy of Sciences USA</i> , 95:12596–12601.
42	IVANOV ET AL. (2001) "Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer." <i>Amreican Journal of Pathology</i> , 158(3):905–919.
43	JEMAL ET AL. (2002) "Cancer Statittics, 2002" CA-Cancer J. Clin., 52(1):23-47.
44	KAPLAN AND MEIER (1958) "Nonparametric estimation from incomplete observations."  Amreican Statistical Association Journal, 53: 457-481.
45	KONONEN ET AL. (1998) "Tissue microarrays for high-throughput molecular profiling of tumor specimens." <i>Nature Medicine</i> , 4(7): 844–847.
46	LIAO ET AL. (1994) "Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas." <i>Amreican Journal of Pathology</i> , 145(3): 598–609.
47	LIAO ET AL. (1997) "Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney." <i>Cancer Research</i> , 57: 2827–2831.
48	LONCASTER ET AL. (2001) "Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix." Cancer Research, 61:6394–6399.
49	KOHLER AND MILSTEIN (1975) "Continuous cultures of fused cells secreting antibody of predefined specificity." <i>Nature</i> 256: 495-497.
50	MOTZER ET AL. (1999) "Survival and prognostic stratification of 670 patients with advances renal cell carcinoma." <i>Journal of Clinical Oncology</i> , 17(8): 2530-2540.
51	MURAKAMI ET AL. (1999) "MN/CA9 gene expression as a potential biomarker in renal cell carcinoma." BJU International, 83: 743–747.
52	OLIVE ET AL. (2001) "Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer," Cancer Research, 61:8924–8929.
Examiner Signature	Date Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 04/30/2003. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A-B/PTO **Application Number** 10/511,465 INFORMATION DISCLOSURE Filing Date October 14, 2004 E STATEMENT BY APPLICANT First Named Inventor Matthew H.T. Bui Group Art Unit Unassigned Unassigned **Examiner Name** ( as many sheets as necessary) 306J-000220US **Attorney Docket Number** Date Submitted March 29, 2005

	\$)	Date Submitted March 29, 2005		
- Calle	7			
TRADE	53	OLSSON AND KAPLAN (1980) "Human-Hunam hybridomas producing monoclonal antibodies of predefined antigenic specificity." <i>Proceeding of the National Academy of Sciences USA</i> , 77(9): 5429-5431.		
	54	OOSTERWIJK ET AL. (1986) "Immunohistochemical analysis of monoclonal antibodies to renal antigens." <i>American Journal of Pathology</i> 123(2):301–309		
	55	OOSTERWIJK ET AL. (1986) "Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney." <i>International Journal of Cancer</i> , 38: 489–494.		
_	56	OOSTERWIJK ET AL. (1996) "Molecular characterization of the renal cell carcinomaassociated antigen G250," <i>Proceedings of the National Association for Cancer Research</i> , 37: #3147.		
	57	PANTUCK ET AL. (2001) "The changing natural history of renal cell carcinoma." <i>The Journal of Urology</i> , 166:1611-1623.		
	58	PARKKILA ET AL. (2000) "Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro." <i>Proceeding of the National Academy of Sciences USA</i> , 97(5):2220–2224.		
	59	PASTOREK ET AL. (1994) "Cloning and characterization of MN, a human tumor associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment." Oncogene 9: 2877–2888.		
	60 PASTOREKOVÁ ET AL. (1992) "A Novel Quasi-viral Agent, MaTu, Is a Two-Compor ystem." VIROLOGY 187 :620-626.			
	61	RAK ET AL. (2002) "What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?" Cancer Research, 62:1931–1934.		
	62	ROILA ET AL. (1991) "Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales." <i>Annals of Oncology</i> 2: 437–439.		
	63	SAARNIO ET AL. (1998) "Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase. MN/CA IX, with potential value as a marker of cell proliferation." <i>Amreican Journal of Pathology</i> , 153(1):279–285.		
	<ul> <li>SCHLOM ET AL. (1980) "Generation of human monoclonal antibodies reactive with hum mammary carcinoma cells." Proceeding of the National Academy of Sciences USA, 77(11):6841-6845.</li> <li>SHEARMAN ET AL. (1991) "Construction, expression, and biologic activity of murine/hum chimeric antibodies with specificity for the human alpha/beta T cell receptor." The Journal Immunology, 146(3): 928-935.</li> </ul>			
	66	SHI ET AL. (1999) "Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic." <i>Clinical Cancer Research</i> , 5:3711–3721.		
		J.,		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid ONB control number.			
Substitute for form 1449A-B/PTO	Complete if Known		
	Application Number	10/511,465	
INFORMATION DISCLOSURE	Filing Date	October 14, 2004	
E STATEMENT BY APPLICANT	First Named Inventor	Matthew H.T. Bui	
	Group Art Unit	Unassigned	
۵۱	Examiner Name	Unassigned	
as many sheets as necessary)	Attorney Docket Number	306J-000220US	
' 3, 圉	Date Submitted	March 29, 2005	

	<b>E</b>	
T& TRADER	67	SLAMON ET AL. (2001) "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2." <i>The New England Journal of Medicine</i> , 344(11):783–792.
	68	SOBIN AND FLEMING (1997) "TNM Classification of Malignant Tumors, 5 Ed" Union Internationale Contre le Cancer and the American Joint Committee on Cancer, Cancer (Phila.) 80: 1803–1804.
	69	STEFFENS ET AL. (1997) "Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250," <i>Journal of Clinical Oncology</i> , 15(4): 1529–1537.
	70	STEFFENS ET AL. (1999) "Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250." <i>Anticancer Research</i> , 19: 1197–1200.
	71	STEFFENS ET AL. (1999) "Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250." Clinical Cancer Research, 5: 3268s—3274s.
	72	STÖRKEL ET AL. (1997) "Classification of renal cell carcinoma: Workgroup No. 1." <u>Union Internationale Contre le Cancer (UICC)</u> and the American Joint Committee on Cancer (AJCC) Cancer, 80(5): 987-989.
	73	TSO ET AL. (2001) "Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor." Cancer Research, 61:7925–7933.
	74	TURNER ET AL. (1997) "MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker." Human Pathology, 28: 740–744.
	75	UEMURA ET AL. (1994) "Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity." <i>International Journal of Cancer</i> , 58: 555–561.
	76	UEMURA ET AL. (1997) "Expression of tumor-associated antigen MN/G250 in urologic carcinoma: potential therapeutic target." <i>The Journal of Urology</i> , 157(4)(Suppl): #1475.
	77	UEMURA ET AL. (1999) "MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas." <i>British Journal of Cancer</i> , 81(4):741–746.
	78	VAN DIJK ET AL. (1989) "Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen." <i>International Journal of Cancer</i> , 43: 344-349.
	79	VISSERS ET AL. (1999) "The renal cell carcinoma associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes." Cancer Research, 59: 5554–5559.
L		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	10/511,465
INFORMATION DISCLOSURE	Filing Date	October 14, 2004
PETATEMENT BY APPLICANT	First Named Inventor	Matthew H.T. Bui
4 E 🖔	Group Art Unit	Unassigned
~ . \	Examiner Name	Unassigned
many sheets as necessary)	Attorney Docket Number	306J-000220US
<sup>8</sup> 3 / 5	Date Submitted	March 29, 2005

	_&/_		
WE TRAD	80	WYKOFF ET AL. (2000) "Hypoxia-inducible expression of tumor-associated carbonic anhydrases." <i>Cancer Research</i> , 60:7075–7083.	
	81	WYKOFF ET AL. (2000) "Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling." <i>Oncogene</i> , 19: 6297–6305.	
	82	ŹAVADA ET AL. (1993) "Expression of MaTu-MN protein in human tumor cultures and in clinical specimens." <i>International Journal of Cancer</i> , 54: 268–274.	
	83	ZISMAN ET AL. (2001) "Improved prognostication of renal cell carcinoma using an integrated staging system." <i>Journal of Clinical Oncology</i> , 19(6):1649–1657.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.